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Background: Eukaryotic cell cycle progression is
regulated by cyclin dependent protein kinases (CDKs)
whose activity is regulated by association with cyclins
and by reversible phosphorylation. Cyclins also deter-
mine the subcellular location and substrate specificity of
CDKs. Cyclins exhibit diverse sequences but all share
homology over a region of approximately 100 amino
acids, termed the cyclin box. From the determination of
the structure of cyclin A, together with results from bio-
chemical and genetic analyses, we can identify which
parts of the cyclin molecule may contribute to cyclin A
structure and function.
Results: We have solved the crystal structure, at 2.0 A
resolution, of an active recombinant fragment of bovine
cyclin A, cyclin A-3, corresponding to residues 171-432
of human cyclin A. The cyclin box has an a-helical fold
comprising five oa helices. This fold is repeated in the
C-terminal region, although this region shares negligible
sequence similarity with the cyclin box.
Conclusions: Analysis of residues that are conserved
throughout the A, B, and E cyclins identifies two exposed
clusters of residues, one of which has recently been shown
to be involved in the association with human CDK2.
The second cluster may identify another site of cyclin A-
protein interaction. Comparison of the structure of the
unbound cyclin with the structure of cyclin A complexed
with CDK2 reveals that cyclin A does not undergo any
significant conformational changes on complex formation.
Threading analysis shows that the cyclin-box fold is
consistent with the sequences of the transcription factor
TFIIB and other functionally related proteins. The struc-
tural results indicate a role for the cyclin-box fold both as a
template for the cyclin family and as a generalised adaptor
molecule in the regulation of transcription.
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Introduction
Progress through the eukaryotic cell cycle depends on
the appropriate activation of members of the cyclin
dependent protein kinase (CDK) family (reviewed in
[1,2]). Members of the CDK family have homologous
sequences which include the subset of residues that are
found in all serine/threonine protein kinases and that are
essential for catalytic activity [3]. CDKs are activated by
binding positive regulatory molecules called cyclins, that
were originally named because of their cyclical accumu-
lation and destruction, which occurs concomitantly with
rapid rounds of division in cleaving embryos of marine
invertebrates and amphibians [4,5]. The subsequent isola-
tion of multiple cyclins has shown that they are diverse in
sequence, sharing homology only over approximately a
100-amino-acid region, now called the cyclin box [6,7].
In higher eukaryotes, cyclins have so far been classified
into eight families (A to H) on the basis of sequence sim-
ilarity and their timing of appearance during the cell
cycle (reviewed in [2]).
Cyclin A is required for progression through S phase
[8-10] and for entry into mitosis [9,11,12]. This dual
function probably stems from the ability of cyclin A to
form stable, active complexes with either CDC2 or
CDK2, unlike the B-type cyclins, which associate exclu-
sively with CDC2, or cyclin E, which forms complexes
only with CDK2. Cyclin A is first detected in late
G1/early S phase [10,13-15], and its expression steadily
rises throughout S and G2. When bound to the kinase,
cyclin A is abruptly degraded, just before the
metaphase--anaphase transition, by ubiquitin-mediated
proteolysis (reviewed in [16]). The binding of cyclin A to
CDC2 (sometimes referred to as CDK1) or CDK2 is a
prerequisite for kinase activity and promotes phosphoryla-
tion on Thrl61 or Thrl60 (for CDC2 or CDK2, respec-
tively), by the CDK-activating kinase (CAK) [17-21].
The role of cyclin A is controversial, partly because it can
form an active protein kinase with either CDK2 or
CDC2. At the start of S phase, cyclin A is detectable in a
stable complex containing CDK2, the transcription factor
E2F, and p10 7 (a protein related to the tumour suppressor
gene product, pRB). This complex can bind to DNA and
has histone-kinase activity [22-25]. E2F-binding sites are
found upstream of a number of genes required for S phase
onset (reviewed in [26]). Binding of cyclin A-CDK2 to
E2F may be an important regulatory interaction linking
progression through the cell cycle with appropriate con-
trol of S-phase-specific gene transcription. The N-termi-
nal sequences of E2F -1, -2 and -3 contain a binding
sequence for cyclin A, and through association with
E2F-1, cyclin A-CDK2 has been shown to phosphorylate
DP-1, the partner of E2F, resulting in decreased DP-1
DNA binding and thus decreased gene transcription in
vitro [27]. Cyclin A also associates directly with p107,
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binding to the p107 linker sequence between the two
consensus pocket sequences (the 'A pocket' and the 'B
pocket') which are essential for E2F binding [28,29].
Whereas association of E2F with cyclin A-CDK2
appears to be important in the regulation of E2F activi-
ties at the beginning of S phase, certain D and E cyclins
have been implicated in releasing transcriptionally active
E2F in G1, from complexes containing E2F and pRB
(reviewed in [2]). Hyperphosphorylation of pRB leads to
the release of E2F, and increased expression of certain
genes (reviewed in [30]). Ectopic expression of cyclin A
gives rise to pRB phosphorylation [31] but in vivo, pRB
hyperphosphorylation occurs at a time in the cell cycle
when cyclin A expression is low [10,13-15].
Cyclin A-CDC2 complexes appear to be required later
in the cell cycle for entry into M phase and are func-
tionally distinct from cyclin B-CDC2 [8,9,11,13,32,33].
The peak of kinase activity associated with cyclin A
occurs before that of cyclin B-CDC2 [13-15], and both
cyclins A and B have to be degraded for cells to exit
mitosis and enter G1 [34].
Cyclins bind to and activate specific CDK partners.
They also mediate the substrate specificity and sub-
cellular localisation of CDKs [35,36]. In order to deter-
mine how these specific binding interactions are
accommodated in cyclin molecules we have determined
the crystal structure of an active fragment of bovine
cyclin A, termed cyclin A-3. Our results are considered
in the light of the recently published structure of the
cyclin A-CDK2 complex [37].
Results
Construction of an active bovine cyclin A fragment
Mutational analysis of cyclin A has shown that a short
peptide sequence of nine amino acids, the destruction
box, situated near the N terminus is required for ubiqui-
tin-mediated degradation (reviewed in [16]). Cyclin A
from which this sequence has been deleted retains
CDC2- and CDK2-binding activity, is constitutively
active, blocks M-phase exit when expressed in vivo, and is
not destroyed [38]. Further N-terminal deletions, that
were carried out on the basis of secondary structure
prediction and the results of limited in vitro proteolysis,
have shown that cyclin A sequences sufficient for CDK
binding and activation of associated kinase activity reside
within a proteolytically stable C-terminal fragment ([38];
J Adamczewski, personal communication). The construct
cyclin A-3 encodes the bovine cyclin A sequence
(EMBL accession no. X68321) beginning at the residue
equivalent to Va1171 in human cyclin A and has a hexa-
histidine tag following Leu432 at the C-terminus
(Fig. 1). (Throughout this manuscript residues are num-
bered according to their equivalent in human cyclin A
[39]). Cyclin A-3-CDC2 complexes, generated by the
addition of bacterially expressed cyclin A-3 to interphase
Xenopus egg extract (which has low levels of endogenous
cyclins), display high histone H1 kinase activity ([38] and
J Gannon, personal communication [data not shown]).
In this assay system, cyclin A-3 can fully activate the
histone-kinase activity of endogenous CDC2. Because
the construct lacks the N-terminal destruction box it
does not undergo ubiquitin-mediated proteolysis. As
described in the Materials and methods section, this
construct formed crystals that diffracted well enough to
allow an unambiguous structure determination.
The structure of cyclin A-3
The feature of the cyclin A-3 structure that is
immediately striking is its high a-helical content. The
structure contains twelve helices of more than one turn
and up to 18 amino acids in length (Fig. 1), arranged in
two lobes linked by two short extended polypeptide
regions (Fig. 2). Helices 1-5 encode a compact N-termi-
nal fold. The N-terminal helix, together with helices
1'-5' and the C-terminal helix, form a larger C-terminal
lobe. The hinge between the two lobes is formed by
residues Lysl94-Gly198, and the extended sequence,
Ala307-Pro309, between helices 5 and 1'. Of the 249
residues (Ile182-Leu430) for which a clear conformation
can be deduced from the electron density, 156 (63%) are
classified as helical by Kabsch and Sander analysis [40].
The first eleven residues and the hexahistidine tag are
poorly defined in the electron density, suggesting that
they may be flexible or disordered.
After this structure determination was completed, the
structure of a human cyclin A-CDK2 complex was
reported [37]. The complexed cyclin was prepared by
proteolytic digestion and corresponds to residues
173-432. The uncomplexed cyclin (this work) was pre-
pared from recombinant bovine cyclin A corresponding
to residues 171-432 in the human sequence. Within this
region there are eight amino-acid differences between
bovine and human cyclin A. An important finding from
a comparison of the structures of free and bound cyclin
A is that cyclin A undergoes no significant structural
change on association with CDK2. The rms (root mean
square) difference is 0.41 A for 252 equivalent Ca atoms.
The cyclin box encodes a compact a-helical domain
Consideration of the intramolecular interactions that
stabilise the cyclin A-3 structure suggests that the cyclin
box runs from Tyr199-Leu306. This defines the limits of
the cyclin box more securely than has been possible by
sequence analysis [6,7,41,42]. The cyclin box itself
constitutes a compact domain consisting of five a helices
(Figs 1,2). The first helix in the fold, helix 1, is the most
highly conserved in the cyclin family. Beginning at
Asn208, it occupies a unique position, contributing sur-
face residues, contact residues to the C-terminal domain
and residues to the cyclin core. The next two helices, 2
and 3, which are largely buried, form the core of the
fold. Residues in helix 2 also contribute to the inter-
domain interface. Helix 3 is predominantly hydrophobic
and interacts extensively, through conserved hydro-
phobic packing interactions, with amino acids in helical
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Fig. 1. Multiple sequence alignment of bovine A-3, representative cyclin B-H sequences, and p25, to illustrate sequence diver-
sity between the different cyclin classes. The results of conservation analysis are shown for the group of A-3, B and E cyclins
(cyclins interacting with CDC2 or CDK2), and for the group of G, F, D, H and C cyclins. Identities within groups are boxed and
coloured blue (for the A, B and E cyclin group) or red (for the C, D, F, G and H cyclin group). Conserved positions are boxed
and coloured yellow. The subset of residues that are identical in multiple A, B and E cyclins are shown by black triangles.
Experimentally determined helices are represented above the alignment as cylinders. Numbers to the left of the sequences indi-
cate the first residues displayed in the alignment. For the A, B and E sequences, structurally equivalent regions in the two
domains are boxed. Sequences shown are A-3 (EMBL accession number X68321), Human B [6], human E [79], rat G [62],
human F [80], human H [21], human C and D [78] and human p3 5 [50]. The figure was generated using ALSCRIPT [76], using
an alignment created by MaxHom [77], manually adjusted to minimise deletions within the secondary structural elements.
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Fig. 2. The fold of bovine cyclin A-3. (a) Cartoon representation of the structure of cyclin A-3. Secondary structure defined by DSSP is
shown by different representations for helices (spiral ribbons) or random coil stretches of protein. The two domains sharing a common
fold (residues 44 (214) to 133 (303) and 141 (311) to 229 (399)) are each colour ramped from blue to red between N- and C-terminal
residues of the equivalent region, so that equivalent parts of the structure are approximately the same colour. Regions not equivalent
between the two domains are coloured grey (residues 11 (181) to 43 (213), 134 (304) to 140 (310) and 230 (400) to 262 (432). Helices
of more than four residues in length are numbered 1-5, and 1'-5' for each of the cyclin folds. The two helices outside these domains
are labelled -N term and c-C term. The view is close to the rough pseudo-twofold axis which relates helices 1-5 with helices 1'-5'.
(b) Stereo Ca trace of cyclin A-3. Every tenth residue is labelled. The view is the same as in (a).
regions 1, 2, 4, and 5. The helices cross the molecule so
that the surface loops linking the N-terminal helix to
helix 1, and helix 2 to helix 3, pack together on one side
of the molecule, and those joining helices 1 to 2 and 3 to
4 are adjacent and on the other side of the structure
(Fig. 2). A search for known protein structures related to
the cyclin fold was performed using the program
STAMP [43]. This identified only a limited similarity
between cyclin A-3 and members of the -helical globin
family (data not shown).
Sequence conservation within the cyclin fold
In the cyclin fold 22 residues are identical in multiple
examples of A, B and E cyclins. These residues (indicated
by inverted triangles in Fig. 1 and coloured yellow in
Fig. 3) are (with one exception) in the N-terminal
cyclin-box fold. Some play a structural role, and others
are exposed and form two notable surface clusters. One
cluster is part of the CDK2-binding site of cyclin A [37]
(Fig. 4) and the second may also identify a site of
cyclin-protein interaction.
Arg211 and Asp240 form a striking buried, conserved
ionic pair in a hydrophobic environment created by the
surrounding residues Tyr199, Ala212, Leu214, Val215,
Val236, Ile239, Leu243, Leu341, Ala344, and
Leu348 (Fig. 5). These residues have conserved hydro-
phobic character in many cyclins (Fig. 1), illustrating the
importance of this region to structural stability. The
Arg211 guanidinium group also makes interdomain
contact, through hydrogen bonds, to the main-chain
carbonyls of Ser340 and Leu341 at the C-terminal end of
helix 2', indicating a possible role for these residues in
domain-domain stabilisation. Mutational analysis supports
the structural evidence that these two residues are essential
for cyclin A activity. Alteration of Arg211 to alanine or
lysine, or alteration of Asp240 to alanine or glutamate
results in loss of the ability of cyclin A to bind to and acti-
vate CDC2 [38,44]. In human cyclin B, conservative
mutation of these residues to lysine-aspartate or argi-
nine-glutamate pairs resulted in proteins that could still
bind CDC2, which became phosphorylated on Tyrl5,
but the complexes containing these mutant cyclins could
not be activated. A double mutation of the arginine
residue and the adjacent alanine to a serine-serine pair
gave a completely inactive cyclin B [45].
Arg241 is partially exposed (Fig. 3b) and is involved in
interactions with the main-chain carbonyl oxygen of
Asp305 which is part of the surface loop that links helices
5 and 1'. Glu295 is also partially exposed and structurally
important (Fig. 3b). This residue interacts with Lys266 in
a hydrophobic surface environment created by Leu262
and Leu263. A number of other conserved amino acids
(Thr231, Leu255, Gly257, Ala264, Phe278, Thr282, and
Met294) are buried. The tight hydrophobic packing
around sequence loci 257 and 264 necessitates that the
residues occupying these positions should be small.
The cyclins A, B and E (i.e. those cyclins that bind to
CDC2 or CDK2 or both) have a marked area of negative
surface charge generated by the folding together of
Glu230 at the end of helix 2, with Glu268 and Glu269 at
the C terminus of helix 3 (Fig. 3b). Above this negative
Crystal structure of bovine cyclin A-3 Brown et al. 1239
Fig. 3. Colour coded CPK models of
cyclin A-3. Residues preceding the
cyclin box (1-37, (171-207)) are
coloured blue, residues of the N-termi-
nal cyclin box domain (38-137,
(208-307)) are coloured cyan, and
residues of the C-terminal cyclin box
domain (138-262 (308-432)) are
coloured magenta. Residues conserved
throughout cyclins A, B, and E, indicated
by an inverted triangle in Figure 1, are
coloured yellow. Residues conserved by
this criterion which present a significant
surface feature are identified by their
residue type (single letter code) and
sequence number (relative to the cyclin
A-3 sequence). The views in part (a) and
(b) are related by 180° rotation around a
vertical axis.
Fig. 4. Location of cyclin A residues in
contact with CDK2. (a) A CPK model.
(b) A ribbon diagram. Contact residues
identified by Jeffrey et al. in the cyclin
A-CDK2 complex structure [37] are
coloured red. Residues that were also
identified by sequence conservation
analysis are labelled and coloured gold
in (a). Helical regions that contribute
contact residues are labelled in (b). The
view in this figure is identical to that of
Figure 3b.
surface, a conserved leucine residue, Leu227, is also
exposed (Fig. 1). The cyclin A-CDK2 structure shows
that these three glutamate residues contribute to the
extended surface of the cyclin A-CDK2 interaction [37]
(Fig. 4). Mutation of Glu230 to glutamine had shown
that, at least in cyclin B, this residue is important in
promoting dephosphorylation and activation of CDC2
[45]. Interestingly, in the D-cyclin family, members of
which bind specifically to CDK4 and CDK6, Glu268 is
replaced by a residue that is positively charged.
On the opposite side of the cyclin box from the CDK2-
binding site, there is a second notable cluster of con-
served residues that may identify another site of
cyclin A-protein interaction. Trp217 and Gln254 are
adjacent and form the core of a conserved surface on the
cyclin A molecule that is shared with the B and E cyclins
(Fig. 3a). Trp217 sits in a cluster of four hydrophobic
residues (Val221, Leu218, Leu214, and Ile213). Other
amino acids in helix 1 (Val215, Asp216, Val219, and
Glu223) pack with complementary sequences in the
C-terminal domain. Adjacent to Trp217, the A cyclins
have a cluster of negatively charged, solvent-accessible
residues at the end of helix 1 (Glu220, Glu223 and
Glu224), whereas the B cyclins share neutral or positively
charged residues in this region (Fig. 1). Two residues in
helix 1, conserved in most cyclins, complete the site:
Met210 and Ile213 (Figs. 1,3a).
The C-terminal domain fold contains a cyclin-box fold
The C-terminal domain starts with residue Thr310, at
the start of helix 1'. Residues 310-432 show very little
sequence conservation between members of the cyclin
family and alignments are difficult. The surprising result
from the determination of the cyclin A-3 structure is
that, although in this region the cyclin sequences share
little sequence similarity with each other or with the
cyclin box consensus sequence, the fold of this domain is
strikingly similar to that of the cyclin box (Fig. 2); for 70
Co positions the rms difference is 1.7 A. Residues
215-303 in the N-terminal domain superimpose on
residues 311-399. Helices 1-5 of the cyclin-box fold are
equivalent, respectively, to helices 1'-5'. Residues in the
C-terminal cyclin-box fold that correspond to those that
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Fig. 5. Refined model and experimental
electron density around the two con-
served residues Arg211 and Asp240.
Electron density is from the DM-modi-
fied MIRAS map at 2.4 A resolution, and
is contoured at the rms value of the
electron density of the map. Arg211 and
Asp240 form a buried salt bridge con-
necting helices 1 and 2. Arg211 is fur-
ther involved in interactions, across the
domain-domain interface, with car-
bonyl oxygens at the end of helix 2'.
interact with CDK2 in the N-terminal fold, are partly
shielded by residues close to the C terminus. In addition,
the C-terminal fold lacks an equivalent to the N-terminal
helix. These structural differences may explain why the
C-terminal domain does not have a CDK-binding site.
Within the cyclin-A family there is strong sequence
conservation in the C-terminal domain, but there is less
conservation between cyclins A and B (one exception
being conservation of Phe314), and almost no detectable
sequence similarity between A-type and E-type cyclins.
There is a cluster of conserved cyclin A residues in the
C-terminal domain at structurally equivalent positions to
the conserved amino acids Trp217, Gln254 and Tyr286
in the cyclin box. Ser353, in the proline-serine motif at
the beginning of helix 3', is equivalent to Gln254;
Phe314, in helix 1', is the C-terminal analogue of
Trp217; and Tyr382, in the loop between helices 4' and
5', is equivalent to Tyr286. The N-terminal helix inter-
acts closely with residues in the C-terminal domain.
His183, Leu186, Argl87 and Glu190 screen Phe314
from the solvent. Glu190 is partly buried and interacts
with side-chain and amino groups of Ser353. Met189
and Cysl93 shield Pro309 from the solvent.
N-terminal deletions of residues up to the equivalent of
residue 176 in the human sequence have no effect on the
function of Xenopus cyclin, but deletion of residues from
183 onwards (the start of the N-terminal helix) results in
loss of activity [38]. The structure of cyclin A-CDK2
confirms that the N-terminal helix contributes residues
required for CDK2 binding [37]. Deletions of the
N-terminal helix would expose conserved hydrophobic
residues in the C-terminal fold and so its loss could affect
the structural integrity of this region.
Phe314 is the first residue in the motif Phe-Leu-
Arg-Arg-X-Ser-Lys (where X is any amino acid), which
is a characteristic of the cyclin B sequences [38]. It is
intriguing that mutational and sequence analysis that
defined regions characteristic of the A- and B-type cyclins
should have identified regions that are equivalent in the
cyclin-box and C-terminal folds, respectively [38,41]. The
residues in the cyclin A-3 structure that are equivalent to
the two arginine and lysine residues in the cyclin B
Phe-Leu-Arg-Arg-X-Ser-Lys motif are on the surface.
Helices 2' and 3', like their counterparts (helices 2 and 3)
in the cyclin box, are hydrophobic and pack into the
core of the fold and again, this is a tightly packed
hydrophobic region. An exception, however, is the
buried glutamate residue Glu338 in helix 2'. This amino
acid forms an ion pair with Lys412 in the C-terminal
helix. Both of these residues are conserved between the
A and B cyclins. The most notable sequence conserva-
tion in the C-terminal domain is the cluster of small
residues in the middle of helix 3' (Fig. 1).
Stabilisation of the domain interface results from
extensive hydrophobic packing between residues Leu341
and Ile342 at the end of helix 2', Leu232 and Val236
from helix 2, and Ala212, Va1215 and Val219 in helix 1.
The helix 2'-helix 3' loop is the site of a 44-amino-acid
insertion in WHI1, a G1 (CLN) S. cerevisiae cyclin [46].
These residues would lie below the surface loop between
the N-terminal helix and helix 1, away from the con-
served surface regions identified by comparative structure
and sequence analysis.
Residues Leu332, Phe335 and Leu339 in helix 2' are
conserved in the A and B cyclins and pack against
hydrophobic residues in the C-terminal helix. Cyclin A
or B constructs with short deletions at the C terminus
cannot bind CDK2 [38,41,42,47]. The cyclin A structure
shows that deletions of the region C-terminal to Ser422
would expose Leu332 to solvent. Further deletions into
the C-terminal helix would increasingly expose the
hydrophobic face of helix 2' and ultimately affect
residues interacting with helix 1. Like deletions of the
N-terminal helix, exposure of buried hydrophobic
residues could affect the folding of this domain.
Sequences compatible with a cyclin-box fold are present in
other regulatory proteins
The two domains of the cyclin A-3 structure illustrate
that proteins with few identities (13%) can adopt similar
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folds. The technique of threading has been shown to be a
sensitive tool for detecting whether an amino-acid
sequence is compatible with a given tertiary structure
[48]. The implementation of the threading algorithm in
the program THREADER [48] produces a pseudo-
energy term from the optimal alignment of an amino-
acid sequence of unknown structure onto a
three-dimensional (3D) template of known structure.
The pseudo-energy term comprises the sum of residue-
to-residue distance-dependent pair potentials resulting
from the optimal threading of sequence onto template.
By comparing a candidate sequence with a library of
potential folds, the technique can identify which of the
potential folds is the most likely to be adopted by the
candidate sequence.
Threading was used, in this case, to test hypotheses from
the literature that the cyclin fold is common to a diverse
family of proteins, extending beyond the previously
recognised cyclin family [49]. For this analysis, candidate
sequences were threaded against a database of 254 folds,
representing diverse tertiary structures and three addi-
tional templates corresponding to the entire structure of
cyclin A-3; the N-terminal region (residues 182-309);
and the C-terminal region (residues 310-430). (Only
results for the entire cyclin structure are shown.) The
candidate sequences used corresponded to p25 , an active
fragment of p35 (the positive regulatory subunit of
CDK5 [50,51]) various portions of human p107 [52],
and transcription factor lIB (TFIIB) [53].
The results of this analysis are summarised in Table 1.
This table presents both the ranking and the filtered
'Z score' of the intact cyclin template, and of the high-
est-scoring non-cyclin template, for each of the candi-
date sequences tested. A ranking of 1 for a given template
indicates that THREADER has identified that template
as the most likely tertiary structure for the candidate
sequence. The filtered Z score is a measure of how many
fold lower (negative) or higher (positive) the energy of a
particular sequence-template threading is, compared with
the average energy observed for that sequence threaded
against all of the templates. Thus, a large negative num-
ber indicates a low energy, and so a high compatibility of
the candidate sequence with a particular template.
According to Jones et al. [54], a Z score of -3.5 or lower
is indicative of a positive result to the analysis.
The most striking result is that the B-pocket sequence of
p107, TFIIB, and p25 all have the cyclin fold ranked 1
(Table 1, rows 3, 5, and 6). Thus, threading lends strong
support to the hypothesis that each of these sequences
contains a cyclin-box-like motif. In the case of p107 and
TFIIB, this hypothesis was advanced by Gibson et al. [49]
on the basis of sequence comparison results using a
profile-based approach. They identified the B-pocket
sequence of p107 as containing a single copy of the
repeated unit present in a cyclin molecule, which they
termed the 'TR' (for TFIIB repeat). We tested this con-
clusion by using the portion of p107 C-terminal to the




2 p107 (A pocket;
252-451)
3 p107 (B pocket;
648-816)






7 UDG (Cyclin box to
C terminus; 193-326)
Cyclin A3 Non-cyclin*
Rankt Score* CODE§ Rankt Scoret
15 -1.8 E1APM 1 -3.0
12 -1.6 A1 COL 1 -3.5
1 -4.2 1 EZM 4 -2.5
73 1.0 A1GDH 1 -2.0
1 -3.6 1OFV 3 -2.8
1 -3.8 A2HHM 2 -3.5
250 -1.4 1ECA 1 -3.1
*Highest ranking template not derived from the cyclin A-3
structure. tPosition in list of potential folds ordered by filtered
Z score. Filtered Z score=(pseudo energy-mean pseudo
energy)/(standard deviation of pseudo energy), where
sequence-template matches involving only small fractions of
the candidate sequence are excluded from the calculations.
§PDB code of the highest ranking non-cyclin template: 1APM,
cAMP dependent protein kinase; 1COL, colicin A; 1EZM,
elastase; 1GDH, D-glycerate dehydrogenase; 10OFV,
flavodoxin; 2HHM, inositol monophosphatase; 1 ECA,
erythrocruorin.
identified TR as a candidate sequence in the threading
protocol (Table 1, row 4). For this candidate sequence,
however, the cyclin templates are uniformly ranked low
down the list of potential tertiary folds, indicating that a
second cyclin-box fold is unlikely in this region.
An alternative possibility, that a second copy of the
cyclin-box fold might constitute the A-pocket sequence
ofplO7, was tested by using the p107 A-pocket sequence
as a candidate sequence in the threading protocol.
Although none of the cyclin templates are ranked 1
(Table 1, row 2), a template corresponding to the first
cyclin-box fold'is ranked fourth, with an energy not far
from that of the preferred template (data not shown).
The most preferred template, with PDB code 1COL, is
the all-helical protein colicin A. We cannot rule out the
possibility that the fold of the A-pocket sequence of
p107 is at least related to the cyclin-box fold on the basis
of this result.
A protein (here termed UDG), produced from a human
genomic DNA library, and that is believed to have uracil
DNA glycosylase activity, has been shown to bear exten-
sive homology to members of the cyclin family [55]. In
this case, the similarity is also limited to the cyclin-box
region, raising the question of whether this protein
contains a single copy of the cyclin-box fold, or whether,
like cyclin A, it contains a tandem repeat of this struc-
tural motif. This was tested by threading the sequence of
UDG that is downstream from the sequence-related
cyclin-box region (Table 1, row 7). Again, none of the
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cyclin templates were ranked 1, but the cyclin-box folds
1 and 2 are both ranked highly (fifth and sixth, respec-
tively, data not shown); thus it cannot be ruled out
that the candidate sequence contains a cyclin-box-like
structural motif. The occurrence of cyclin-box folds in
some of these proteins is summarised in Figure 6.
The catalytic core domain of phosphorylase kinase was
included as a negative control. This protein, which is of
similar length to cyclin A-3, exhibits a classic kinase fold
composed of a P sheet and an or-helical domain. Thread-
ing showed that this sequence is not compatible with the
cyclin fold (Table 1, row 1) but is compatible with that of
the cyclic AMP dependent protein kinase structure (PDB
code 1APM), with a filtered Z score of-3.0. This result
gives further confidence in the ability of the threading
algorithm to distinguish correct folds.
Discussion
The cyclin box
Cyclins are a sequence-diverse family of proteins that are
essential for CDK activity. Sequence alignments have
previously shown that cyclins share a conserved region
of approximately 100 amino acids in the centre of the
molecule, and these comparisons, together with the
results of site-directed mutagenesis, supported the idea
that this region is essential for CDK binding and activa-
tion. The determination of the crystal structure of cyclin
A-3 now shows that the cyclin box sequence encodes a
compact five-helical domain. The cyclin-box fold is
highly structured and there are no extended loops.
Notably, the diverse cyclin sequences are very similar in
length over the cyclin box, with the exceptions of the
CLN-encoded cyclins. The cyclin A structure, however,
Fig. 6. A schematic representation of the occurrence of cyclin-
box folds. Cyclin-box folds are denoted in black. In cyclin A (this
work) the upper numbers refer to the full length cyclin A mole-
cule. In pRB and p107 the numbering of the A-pocket sequence
is according to [521, and the numbering in the B-pocket
sequence corresponds to that of the sequences with similarities
to TFIIB and cyclin, identified by [49]. For TFIIB the numbering
of the domains is according to [49].
shows that the insertions present in the Clns could easily
be accommodated in a surface loop.
Comparison with cyclin A-CDK2
A comparison of the structure of cyclin A-3 with that of
cyclin A-CDK2 [37] reveals no significant structural
changes between the free and bound forms of cyclin
A-3. In striking contrast, CDK2 undergoes a significant
conformational response on complex formation that
results in activation of the enzyme. The surface of cyclin
A-3 thus appears to provide a rigid template against
which the CDK responds to produce a complementary
surface. These comparisons show a rigid regulatory
molecule and a pliable enzyme structure.
The surface residues of cyclin A-3 identified in the
complex as being important for complex formation
include the exposed surface patch of Glu268 and Glu269
and the residues Met294 and Glu295. These residues
were also identified as conserved surface residues from
sequence conservation of the A, B and E cyclins in this
analysis of the free cyclin structure. The cyclin A-CDK2
interface, however, also contains other cyclin A residues
that are not completely conserved in these other cyclins,
suggesting that amino-acid differences can be tolerated
within this binding region. The highly conserved patch
identified in this work, that includes Trp217 and
Gln254, is not involved in the interface with CDK2 and
it may be that this region plays a role in mediating con-
tacts to other protein partners. The recently identified
CDK inhibitors p21 and/or p27 are attractive candidates
for those partners (reviewed in [2]). One model that can
be envisaged is that those molecules that directly regulate
kinase activity bind to the highly conserved N-terminal
cyclin-box fold, whereas molecules that effect localisa-
tion or regulate the complex, such as p107, bind to the
C-terminal cyclin-box fold.
Although there is little (13%) sequence identity between
the two domains of the cyclin A-3 structure, these
sequences adopt similar folds. This result parallels the
observation that, even within the cyclin box, diverse
cyclins do not share identity at residues that appear
important for the structural integrity of cyclin A. A
number of protein classes are found that share similar 3D
structures but no sequence identity (reviewed in [56]).
The tandem duplication of the cyclin-box structure in
cyclin A was predicted by extensive cyclin-sequence
analysis [49]. The sequence similarity that suggested the
tandem duplication in the cyclin structure centred on the
conserved sequence of alanine and small hydrophobic
residues that are now shown to comprise helices 3 and 3',
respectively. The structural importance of these residues
is emphasised by their conservation in diverse cyclin-box
fold sequences.
Implications for other cyclins
Sequence alignment suggests that the structures of
cyclins G and H are compatible with a tandemly dupli-
cated cyclin-box fold. Cyclin H, together with CDK7,
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constitutes CAK, the CDK-activating kinase [21,57].
CAK was re-isolated as an integral component of tran-
scription factor IIH (TFIIH) which phosphorylates the
C-terminal domain of the largest subunit of RNA poly-
merase II [58-61]. Alignment of cyclin H with cyclin A
shows that cyclin H would contain little more than the
duplicated cyclin-box fold (Fig. 1). Intriguingly, the
naturally occurring first residue of cyclin H corresponds
to the first residue of cyclin A-3, the sequence of which
has been identified by mutational analysis to be the
minimum required for CDK binding and catalytic activ-
ity [38]. The cyclin H sequence is-of sufficient length to
encode a helix equivalent to the N-terminal helix. This
helix, lying outside the cyclin-box fold but in intimate
contact with residues in the C-terminal domain, may be
a conserved feature of CDK binding. The cyclin
A-CDK2 structure shows that this helix contributes
residues to the CDK2-binding site [37]. A counter
example is cyclin G which, by sequence alignment,
starts at helix 1 and lacks the N-terminal helix. A CDK
partner for cyclin G has, however, not been isolated and
its function is still unknown [62].
Threading analysis strongly suggests that p2 5, an active
proteolytic fragment of p35, [50,51] a CDK5 partner and
activator with essentially no sequence similarity to
cyclins, shares structural similarity to the cyclins. p25
results from an N-terminal deletion of 98 residues from
the p35 sequence. Alignment from the threading against
cyclin A-3 shows that the sequence is not long enough
to encode two complete cyclin-box folds. This result
suggests that, at least for the CDK5-p25 complex, a
second cyclin-box fold is not required for the positive
regulatory function of p25.
Structural similarity with TFIIB and other functionally
related molecules
A wider role for the cyclin fold as a more generalised
adaptor motif is supported by the results of threading
analysis, which show that sequences compatible with the
cyclin-box fold are to be found in a wide range of regu-
latory molecules, most notably the transcription factor
TFIIB and the B pocket of the tumour suppressor gene
products pRB and the related protein, p107 (Fig. 6). The
B-pocket sequence in pRB and p107 is part of a bipartite
binding domain required for their association with the
transcription factor E2F/DP [63]. The results presented
in this paper are consistent with at least one of the
regions associated with E2F binding having a compact
fold. Still to be determined are the relative contributions
of the B-pocket sequence (compatible with a cyclin-box
fold) and the A-pocket sequence to the binding of
E2F/DP to the pocket-protein family. Sequence similar-
ity between the pRB A-pocket sequence and TFIID, and
between the pRB B-pocket sequence and TFIIB, has
been reported previously [64]. This result provides
additional supporting evidence for a model in which the
A and B pocket sequences encode independent (but pos-
sibly cooperative) structures. Intriguingly, the cyclin fam-
ily, the pocket-protein family, and UDG, have all been
functionally linked to E2F activity. In the case of the
association of E2F-1 with UDG, the suggestion was
made that UDG and E2F-1 may interact biochemically
[65], although the authors stated that no evidence was
available to support the contention. The fact that a
sequence compatible with the cyclin-box fold is impor-
tant for E2F binding in pRB supports the contention
that UDG may directly bind E2E
The discovery that molecules controlling progression
through the cell cycle are also closely involved in regulat-
ing gene transcription has been one of the most exciting
recent developments in these two fields. The determina-
tion and analysis of the structure of cyclin A strongly sug-
gests that a number of molecules important to both
processes share the cyclin-box fold as a structural motif.
Within the cyclin family, the concentration of conserved
residues in the N-terminal cyclin box suggested that this
region of these molecules is responsible for their shared
function of CDK binding. The unique properties of the
different cyclins may be associated with the other
domains of the proteins of this family. The characterisa-
tion of protein binding to the cyclin-box fold will be a
productive and illuminating task.
Biological implications
Cyclins are a diverse family of proteins that have
only limited sequence similarity but share the
common function of activating members of the
cyclin-dependent kinase (CDK) family. The activ-
ity of cyclin-CDK complexes can be further regu-
lated by both phosphorylation and association
with additional proteins. Seven CDK and eight
cyclin classes have been identified in higher
eukaryotes. The CDKs share sequence similarity
and are structurally homologous to other protein
kinases. The cyclins, however, share only limited
homology within the cyclin-box sequence. CDKs
undergo large changes in conformation on bind-
ing cyclins but the crystal structure of unbound
cyclin now shows that cyclin conformation does
not change significantly. Instead, it provides a
rigid surface of complementary architecture to
the active CDK.
The structure of cyclin A-3, an active recombi-
nant fragment of bovine cyclin A, shows that the
cyclin box encodes a novel protein fold compris-
ing a five-helix bundle that is tandemly repeated
in the C-terminal domain. Sequence comparison
between the A, B and E cyclin classes, which
bind CDK2 and /or CDC2, shows that there are
two surface clusters of conserved residues in the
cyclin-box fold. One cluster is part of the
extended surface of cyclin A-CDK2 interaction.
The second is on the other side of the molecule
and may identify an additional site of cyclin-
protein interaction. The cyclin A structure pro-
vides a framework for sequence analysis aimed at
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determining the origins of the similarities and dif-
ferences between the cyclin classes in the binding
of CDK and other proteins.
Threading analysis has been used to test the extent
to which the cyclin-box motif occurs in a range of
regulatory proteins, including the transcription
factor TFIIB and the B-pocket sequence of the
pocket proteins. The results of this analysis
strongly suggest that the cyclin-box fold is present
in the extended cyclin family and, as previously
proposed, in a number of molecules that regulate
transcription. We propose that the cyclin box
encodes a structurally stable protein fold that,
through protein-protein association, can modulate
the activity of a number of molecules involved in
the regulation of the cell cycle and transcription.
Material and methods
Expression and purification of cyclin A-3
A cDNA fragment encoding the bovine cyclin A sequence
(equivalent to that of human cyclin A from Vall71 to the C ter-
minus) was amplified by PCR and cloned into the bacterial
expression vector pET21d (Novogen, Madison, WI). PCR
amplification introduced a methionine residue at the N terminus
and changed the next residue in the sequence from serine to
glycine. Subsequent amino-acid sequencing showed that the N-
terminal residue of cyclin A-3 is a glycine. This construct also
modified the bovine sequence by introducing six consecutive
histidine residues following the C-terminal valine. Protein
expression was induced in E. coli B834/LYS-S cells in log-phase
by addition of IPTG to a concentration of 0.1 mM, followed by
incubation at 37°C for 30 min, then at 30°C for 3 h. The E. coli
cell pellet was harvested by centrifugation and resuspended in N
buffer (300 mM NaCl, 0.01% monothioglycerol, 0.01% NaN 3,
50 mM Tris-HC1, pH 7.5) containing added protease inhibitors,
(0.1 mM PMSF, 0.7 Rjg ml-l pepstatin, 0.5 pIg ml- leupeptin,
0.1 mM benzamidine), 20 pg m-1 DNAase, 20 g ml-1
RNAse, 0.1% Triton X-100 and 10 mM MgC12. Following cell
lysis by freeze/thaw, the lysates were incubated on ice for 30
min, then centrifuged at 1000g for 20 min at 4C. The
cleared lysate was immediately loaded onto a Ni-NTA column
(QIAGEN) equilibrated in N buffer and eluted with a linear
gradient of imidazole (0.0-0.5 M) in N buffer. Fractions con-
taining cyclin A-3 were identified by SDS-PAGE and pooled,
and MgC12 was added to a final concentration of 0.1 M. MgC12
addition appears to be essential at this stage of the preparation to
prevent further protein aggregation. The volume of the pool
was reduced to approximately 5 ml (Centriprep, Amicon, Bev-
erly, MA) before gel filtration on Superdex75 (HR26/60, Phar-
macia, Uppsala, Sweden) equilibrated in 0.1M MgC1 2, 0.01%
monothioglycerol, 0.01% NaN 3, 50 mM Tris-HC1, pH 8.5.
Cyclin A-3 eluted in two peaks, the first corresponding to
oligomeric aggregates and the second consistent with a
monomer population. This latter peak was pooled and concen-
trated to 5-10 mg ml-' (Centricon, Amicon) for crystallisation
trials. Approximately 10 mg of cyclin A-3 of sufficient purity for
crystallisation trials was produced from 1 L of bacterial cell cul-
ture. Dynamic light scattering measurements (M801 Molecular
Size Detector, Protein Solutions Inc., Charlottesville, VA)
confirmed the monodispersity of the cyclin A-3 preparation.
Cyclin A-3 appears to be stable when stored under these
conditions at 4C for several weeks.
Cyclin A-3 crystallisation
Initial crystallisation conditions were identified following
screening using sparse matrix sampling conditions (Crystal
Screen, Hampton Research, Riverside, CA). Cyclin A-3
crystals were grown using the sitting drop vapour diffusion
technique at 200C. Typically 1-2 *1l of cyclin A-3, at
5-10 mg ml-' in 0.1 M MgC12, 0.01% monothioglycerol,
0.01% NaN 3, 50 mM Tris-HC, pH 8.5, were mixed with an
equal volume of 25-26% methoxyPEG 5K (Fluka, Buchs,
Switzerland) containing 0.2 M LiSO 4 and 0.1 M Tris-HC1,
pH 7.0-7.5 and allowed to equilibrate with 1 ml of the same
buffer. Crystals appeared within one week, and had a
tendency to be plate-like (typically 100-200 Ixm by
50-75 Km and rarely thicker than 10 pxm), with clustered
growth. Extensive screening around these conditions failed to
eliminate these problems.
Data collection and processing
Cyclin A-3 crystallised in the orthorhombic spacegroup
P212121 and with unit-cell dimensions (at 100 K) a=52.7 A,
b=60.9 A, c=83.5 A. There is one molecule of cyclin A-3 (262
amino acids; 32417 Da) per asymmetric unit, giving a
Vm=2.18 A3 Da-', which indicates a solvent content of
approximately 30%. Because the crystals were typically only
5-10 ,am in the smallest dimension, data could only be col-
lected at Synchrotron Radiation Sources. All data sets were
collected at 100 K, and crystals were soaked in cryoprotectant
(30% methoxyPEG, 0.2 M LiSO 4, 15% glycerol, 0.1 M Tris,
pH7-7.5) 5 min before mounting, using the method of Teng
[66]. An initial native data set was collected at beamline 9.6 of
the Daresbury SRS at a wavelength of 0.87 A, with a crystal-
to-detector distance of 300 mm on a 30 cm Mar Research
imaging plate detector, giving a resolution of 1.9 A at the edge.
Data were collected with individual oscillations of 1.5° and
exposures of approximately 2 min. Subsequent screening of
heavy atom compounds was carried out at both the ESRF,
BL4 and at Daresbury stations 7.2 and 9.6. BL4 was operating
at a wavelength of 0.993 A, equipped with a Mar30 imaging
plate set at a distance of 200 mm, giving a resolution of 2.4 A
at the edge of the plate. Typically images were collected over
2° oscillations, with 10 s exposures. Further derivative data and
an improved native data set were collected at Daresbury station
7.2 operating at a wavelength of 1.488 A. Data were collected
on a Marl8 imaging plate detector set to give either 2.0 A or
2.4 A resolution at the edge, with oscillations of 1.5° and typi-
cal exposures of 180 s. The images were integrated with the
DENZO package [67], and reflections were subsequently
scaled and merged using SCALEPACK [67]. Structure factors
were derived from intensities by the program TRUNCATE
from the CCP4 package [68]. Statistics of the data sets used in
the structure determination are given in Table 2.
Structure solution and refinement
A single mercury site was identified in the =0.993 A ETMS
data set by inspection of the Harker sections of an anomalous
Patterson. Phases from this data set were used in difference
Fouriers to identify sites in the EMP derivative and in the
ETMS derivative collected at X=1.488 A. All three derivatives
shared one common site, with the EMP derivative having
three subsidiary sites, and the =1.488 A EMTS data set hav-
ing one subsidiary site. All other potential derivatives were
found to contain either no interpretable heavy atom sites, or
only the major site. Heavy atom refinement and phasing were
carried out to the limit of available data for each derivative
(typically 2.4 A) using MLPHARE [69]. Statistics of the phas-
ing are summarised in Table 2. Only one of the two possible
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enantiomeric heavy atom structures gave an MIR map with a
defined solvent boundary. Phases from this procedure were
improved through density modification by the program DM
[70], taking advantage of the solvent flattening, histogram
matching, and Sayre's equation options in a resolution-based
extension scheme, beginning at 4.5 A and extending to 2.4 A.
The resulting phases were used to calculate a map at 2.4 A
resolution which was skeletonized by the BONES algorithm
[71]. ot-helical stretches could clearly be seen in the skeleton,
allowing an essentially complete model to be built directly,
with the exception of the N and C termini, and the connec-
tion between helices 1' and 2'. The map was of sufficient qual-
ity to allow unambiguous assignment of the sequence on the
basis of features in the electron density.
Refinement of the structure at 2.0 A resolution was pursued by
alternate cycles of Simulated Annealing refinement using
X-PLOR [72] and manual refitting using [71]. In the
X-PLOR refinement, a 2r cutoff was applied to the data. The
C terminus could be completed in the first 2Fo-Fc map up to
residue Leu432, corresponding to the last genuine residue of
bovine cyclin A. When the conventional R factor reached 25%,
waters were included in the model with the help of the program
ARP [73]. Statistics of the refined structure are given in Table 2.
Structure analysis
After refinement, the structure was analysed for geometric
quality using the PROCHECK package [74]. This awarded the
structure a 'G-value' more than two standard deviations better
than the mean for structures of the same nominal resolution.
The equivalence of the N and C terminal domains was
identified by the program STAMP [43], which aligned 66 Cot
positions of the N and C-terminal cyclin domains with a rms
agreement of 1.8 A. This alignment was improved using the
program O [71]. A STAMP comparison of the cyclin fold with
a data base of other known structures revealed some similarity
with members of the globin superfamily. For this comparison,
however, only some 40 Cao positions could be equivalenced,
corresponding to four of the helices of the cyclin fold.
Threading analyses
Comparison of other potential cyclin-fold sequences with
the cyclin structure was performed with the program
THREADER [48]. This program performs an optimal align-
ment of a candidate sequence against a known structure, with a
scoring table based on distance and residue-type dependent pair
potentials. Candidate sequences were threaded separately onto
the intact cyclin fold, and the two cyclin-box domains that
constitute the cyclin fold (results not shown). To achieve a
measure of significance of the scores, the candidate sequences
were also threaded against a data base of 254 different folds
provided with the program. Default parameters were used
except for a 'd-value' of 200, and an 'x-value' of 1. These two
parameters govern the depth of search used in sequence align-
ment, and the gap-extension penalty, respectively. A d-value of
200 increases the program's chances of establishing the correct
alignment between candidate sequence and the trial structure,
while an x-value of 1 discourages long insertions or deletions
in the sequence-structure alignment. Candidate sequences
threaded included the p2 5 construct, which is a fragment of
p35 (residues 99-307), domain A of human p07 (residues
252-451), domain B of human p107 (residues 648-816), the
C-terminal portion of human p107 (residues 817-935), intact
human transcription factor IIB (TFIIB, residues 1-316), and
the C-terminal portion of human uracil deglycosylase starting
Table 2. Statistics of the data sets used and of the refined structure.
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11 -262, and 174 water molecules)
Redundancy of the native data set is 4.1.
tRmerge= Ij llh,j-Ih l/ l l
where ]hj is the jth observation of reflection h.
*:Riso=~ I IFphhl- FPhl / lFPhl
where Fph h and FPh are the measured structure factor amplitudes for
reflection h in the derivative and native data sets, respectively.
§Phasing power=lFhca 1cl/E
where Fhcalc is the calculated structure factor amplitude of reflection h
due to scattering by the heavy atoms, and E is the residual lack of
closure error.
#Rcurlis=il l Fphh±Fphl-lFhcalchl l/ lFphh+FPhl
where Fph h and FPh are the measured structure factors for centric
reflection h in the derivative and native data sets, respectively, and
Fhcalc h is the calculated structure factor amplitude of reflection h due
to scattering by the heavy atoms.
Rcon.. -11Fobshl-lFcalchIl/ lFobShl,
where Fobsh and Fcalc h are the observed and calculated structure
factor amplitudes, respectively, for reflection h.
ttRf,ee is equivalent to Rconv for a five percent subset of reflections not
used in the refinement. *Gvau e is the overall measure of structure
quality from the PROCHECK package [741. Higher numbers are
indicative of a better structure. The mean G value for protein structures
determined at 2.0 A resolution is approximately -0.4.
just beyond the previously identified cyclin box motif of this
protein (residues 193-326). As an additional control, the
sequence of a truncated form of the y-subunit of phosphorylase
kinase, which is known not to have a cyclin fold [75], was
threaded against the database of known folds and the cyclin
fold. Results of these analyses are summarised in Table 1.
The coordinates have been submitted to the Brookhaven
Protein Data Bank.
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Note added in proof
The crystal structure determination of the transcription factor
TFIIB in complex with the TATA box binding protein and DNA
(Nikolov, D.B. et al., Nature 377:119-128), and the NMR deter-
mination of free TFIIB (Bagby, S. et al., Cell 82:857-867) have
shown that the transcription factor TFIIB does contain a repeat
cyclin-box fold in agreement with the result presented here.
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